You are here
Articles
Posted on Sunday, March 10, 2013 - 3:03pm
Suboptimal Responses in Chronic Myeloid Leukemia
Elias Jabbour, MD,1 Giuseppe Saglio, MD, PhD,2 Timothy P Hughes, MD,3 and Hagop Kantarjian, MD1
Abstract
The high response rates and increased survival associated with...
Posted on Wednesday, March 6, 2013 - 1:52pm
Susan Branford 1,2
1 Department of Genetics and Molecular Pathology, Centre for Cancer Biology, SA Pathology, Adelaide,
Australia; and 2 University of Adelaide, Adelaide, Australia
Monitoring response...
Posted on Wednesday, March 6, 2013 - 1:50pm
David T. Yeung 1-3 and Susan Branford 1,3
Posted on Wednesday, March 6, 2013 - 1:45pm
David Marin
Hammersmith Hospital, Imperial College London, London, United Kingdom.
Posted on Saturday, March 2, 2013 - 3:29pm
"...Three months ago, my PCR result was .07% (or 0.0245% on the IS). It doesn’t take a genius (I wish it literally did take a genius) to see that the results aren’t as good as they were three months ago. However, it’s...
Posted on Thursday, February 28, 2013 - 12:31pm
“Borne Out of Necessity and Data”: Conquering Mutations in Leukemia
By Jessica Wapner
'A couple of months ago, the FDA approved the latest drug to treat chronic myeloid leukemia (CML). Called ponatinib (brand name...
Posted on Wednesday, February 27, 2013 - 9:29pm
Transferred WT1-Reactive CD8+ T Cells Can Mediate Antileukemic Activity and Persist in Post-Transplant Patients
Aude G. Chapuis1,*, Gunnar B. Ragnarsson1,*,†, Hieu N. Nguyen1, Colette N. Chaney1,...
Posted on Friday, February 22, 2013 - 9:02pm
'Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD'
Catherine C. Smith, Elisabeth A. Lasater, Xiaotian Zhu, Kimberly C. Lin, Whitney K. Stewart, Lauren E. Damon, Sara...
Posted on Wednesday, February 6, 2013 - 12:07pm
Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies
Pratap Neelakantan1, Gareth Gerrard1, Claire Lucas2, Dragana Milojkovic1, Philippa May1...
Posted on Monday, February 4, 2013 - 1:58pm
The findings are published in the Dec. 24 online early edition of the Proceedings of the National Academy of Sciences (PNAS).
Posted on Saturday, January 26, 2013 - 8:10pm
The U.S. Food and Drug Administration today approved a new use of Gleevec (imatinib) to treat children newly diagnosed with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).
Posted on Thursday, January 24, 2013 - 11:00am
Funding for new research to improve leukaemia treatment by investigating how cancer cells use hiding places in the body to avoid chemotherapy drugs.
Posted on Tuesday, January 22, 2013 - 1:50pm
On 17 January 2013, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product Bosulif 100 mg and...
Posted on Tuesday, January 8, 2013 - 11:47am
Evaluation of the Impact of Switching CML Patients Treated with a First-line Tyrosine Kinase Inhibitor to Ponatinib
CAMBRIDGE, Mass. & LONDON--(BUSINESS WIRE)--Jan. 7, 2013-- ARIAD Pharmaceuticals, Inc. (NASDAQ:...
Posted on Friday, January 4, 2013 - 12:50pm
Paper:3782 'Change in Chronic Low-Grade Non-hematologic Adverse Events (AEs) and Quality of Life (QoL) in Adult Patients (pts) with Philadelphia Chromosome–Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-...
- ‹ previous
- 16 of 33
- next ›